The Change of Serum Insulin-Like Growth Factor Binding Protein 3 (IGFBP-3) in the Diagnosis and Management of Prostate Cancer.
- Author:
Hyung Jin KIM
1
;
Pyoung Han HWANG
;
Ho Keun YI
;
Jung Ho YOUM
;
Dae Yeol LEE
Author Information
1. Department of Urology, Pediatrics Chonbuk National University Medical School, Chonju, Korea.
- Publication Type:Original Article
- Keywords:
Prostate;
Cancer;
Insulin-like growth factor;
Protein;
Tumor marker
- MeSH:
Diagnosis*;
Humans;
Insulin-Like Growth Factor Binding Protein 3*;
Neoplasm Grading;
Prostate*;
Prostatic Hyperplasia;
Prostatic Neoplasms*
- From:Korean Journal of Urology
2001;42(7):713-717
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: Insulin-like growth factor binding protein 3 (IGFBP-3) binds to IGF and acid labile subunit in blood, that regulates the action of IGF by modulating the interaction of IGF with the IGF receptor. Recent studies have shown that IGFBP-3 levels are decreased in prostate cancer patients. We examined IGFBP-3 profiles in prostate cancer patients and determined the effect of treatment on serum IGFBP-3 level in those patients. MATERIALS AND METHODS: Control groups were composed of age-matched healthy subjects and patients with benign prostatic hyperplasia (BPH). Patients with prostate cancer were divided into localized, locally advanced, metastatic and hormone-refractory. Serum samples were collected and stored at 70oC until use. The IGFBP-3 profile was measured by Western ligand blots. RESULTS: The serum IGFBP-3 level in patients with prostate cancer was significantly lower than healthy subjects or patients with BPH. Following the treatment of prostate cancer, IGFBP-3 was increased compared to that seen in pretreated prostate cancer. In hormone-refractory prostate cancer, IGFBP-3 was decreased again. However, there was no correlation between IGFBP-3 and tumor stage or Gleason score. CONCLUSIONS: These data show that IGFBP-3 levels are decreased in pretreated and hormone-refractory prostate cancer. Our results demonstrate that serum IGFBP-3 may be a useful marker in the detection and management of prostate cancer.
